---
title: "ALPHAMAB-B: JSKN003 has once again received breakthrough therapy designation from CDE"
description: "ALPHAMAB-B's JSKN003, developed in collaboration with a subsidiary of CSPC Pharmaceutical Group, has received breakthrough therapy designation from the CDE for patients with HER2+ advanced CRC who hav"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261787498.md"
published_at: "2025-10-20T00:38:03.000Z"
---

# ALPHAMAB-B: JSKN003 has once again received breakthrough therapy designation from CDE

> ALPHAMAB-B's JSKN003, developed in collaboration with a subsidiary of CSPC Pharmaceutical Group, has received breakthrough therapy designation from the CDE for patients with HER2+ advanced CRC who have failed treatment with oxaliplatin, fluorouracil, and irinotecan. CRC has a high incidence rate in China, and existing therapies have limited effectiveness. JSKN003 has shown significant efficacy and good safety, meeting the clinical needs of this patient population

According to the Zhitong Finance APP, ALPHAMAB-B (09966) announced that its JSKN003, developed in collaboration with the subsidiary of CSPC Pharmaceutical Group Limited (stock code: 1093), has received breakthrough therapy designation from the CDE for the treatment of HER2+ advanced CRC patients who have previously failed treatment with oxaliplatin, fluorouracil, and irinotecan. Previously, JSKN003 had also received breakthrough therapy designation from the CDE in March 2025 for the treatment of PROC, regardless of HER2 expression levels.

CRC is one of the most common malignant tumors globally. In China, the incidence of CRC ranks second after lung cancer, with over 500,000 new cases each year and a continuous upward trend. Currently, there are no approved anti-HER2 targeted drugs for CRC in China. For HER2+ advanced CRC patients who have failed treatment with oxaliplatin, fluorouracil, and irinotecan, the approved therapies have a median progression-free survival (mPFS) of only 2.0-3.7 months and a median overall survival (mOS) of about 7-10 months. There remains a significant unmet clinical need in this patient population.

The company previously presented a summary analysis of two clinical studies on JSKN003 monotherapy for advanced HER2 high-expressing (IHC3+) gastrointestinal tumor patients at the 2025 American Society of Clinical Oncology (ASCO) annual meeting. The results showed that JSKN003 monotherapy has significant efficacy in treating HER2 high-expressing advanced CRC patients, with good safety profiles. This summary analysis included a Phase I clinical study conducted in Australia (JSKN003-101) and a Phase I/II clinical study conducted in China (JSKN003-102). As of February 28, 2025, a total of 50 HER2 high-expressing advanced gastrointestinal tumor patients (23 of whom had CRC) were included in the two studies, with 38% of patients having previously received ≥3 lines of anti-tumor treatment. The study results indicated that among the 21 HER2 high-expressing CRC patients who had at least one tumor efficacy assessment, the objective response rate (ORR) was 61.9%, the disease control rate (DCR) was 95.2%, the mPFS was 13.77 months, and the median duration of response (mDoR) was 12.06 months. Among the 20 BRAF V600E wild-type CRC patients, the ORR reached 65.0%. In terms of safety, among the 43 patients who received the recommended Phase II dose (RP2D), only 6 patients (14.0%) experienced grade 3 or higher treatment-related adverse events (TRAEs), 3 patients (7.0%) experienced treatment-related serious adverse events (TRSAEs), and 7 patients (16.3%) had dose reductions due to TRAEs. No TRAEs led to treatment discontinuation or death.

JSKN003 is a targeted HER2 bispecific antibody-drug conjugate (ADC) that connects a topoisomerase I inhibitor to the N-glycosylation site of the KN026 antibody (a recombinant humanized bispecific anti-HER2 antibody) through glycosylation point coupling technology. The click reaction conjugate during the coupling process has better serum stability than the maleimide-Michael reaction conjugate. The targeted HER2 bispecificity gives JSKN003 stronger endocytic activity and bystander killing effects, providing it with strong anti-tumor activity in HER2-expressing tumors In September 2024, our company reached an authorized cooperation with Shanghai Jinmant Biotechnology Co., Ltd. to develop, sell, promise to sell, and commercialize JSKN003 in mainland China for the treatment of tumor-related indications. Currently, three Phase III clinical trials of JSKN003 for HER2+BC, HER2 low-expressing BC, and PROC are underway

### Related Stocks

- [09966.HK - ALPHAMAB-B](https://longbridge.com/en/quote/09966.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Mikrobiomik 获得了用于治疗艰难梭菌感染的肠道微生物群疗法的批准 | Mikrobiomik 已在西班牙获得其口服疗法 EUTEGRA (MBK-01) 的批准，用于治疗艰难梭菌感染，标志着其成为首个为此目的处理粪便微生物群的组织。该疗法采用 FSPIM 技术，为传统抗生素治疗提供了一种替代方案。此次批准是在 | [Link](https://longbridge.com/en/news/276345316.md) |
| 美股盘中速递：Mangoceuticals 股价暴涨 71.58%，注射睾酮疗法销售激增成增长引擎！ | Mangoceuticals 涨 71.58%；SRX Health Solutions 跌 2.11%，成交额达到 57.33 万美元；1 药网成交额达到 541 美元；Ridgetech 成交额达到 46 美元。 | [Link](https://longbridge.com/en/news/276453115.md) |
| 缅因州疾病控制与预防中心报告称，缅因州已确认新增 4 例麻疹病例 | 缅因州疾病控制中心报告缅因州新增 4 例麻疹确诊病例 | [Link](https://longbridge.com/en/news/276164223.md) |
| ECCO 2026 的数据验证了 Iterative Health 的站点网络模型，以加速和提高试验执行的一致性 | Iterative Health 宣布在 ECCO 2026 大会上发布了一项研究，展示了其站点网络模型如何提升临床试验的执行效率。研究显示，他们的网络在患者招募率方面超越了行业基准，平均每月招募率为 0.34，显著高于行业平均水平。激活时 | [Link](https://longbridge.com/en/news/276333779.md) |
| 癌症与血液疾病中心为德克萨斯州患者革新了 CAR-T 癌症治疗的提供方式 | 癌症与血液疾病中心已启动一项计划，在德克萨斯州的社区医疗机构提供 CAR-T 疗法，显著扩大患者对这一先进癌症治疗的获取。该中心与当地医院合作，正在治疗首位患者，一名 62 岁的 B 细胞淋巴瘤男性患者。此项举措是在德克萨斯州通过 3057 | [Link](https://longbridge.com/en/news/276139832.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.